(S (NP (NNP Prostate) (NN cancer)) (VP (MD can) (VP (VB be) (ADJP (VBN lethal)) (PP (IN in) (NP (NP (JJ advanced) (NNS stages)) (, ,) (SBAR (WHPP (IN for) (WHNP (WDT which))) (S (NP (NN chemotherapy)) (VP (MD may) (VP (VB become) (NP (DT the) (JJ only) (JJ viable) (JJ therapeutic) (NN option)))))))))) (. .))
(S (SBAR (IN While) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT no) (JJ clear) (JJ clinical) (NN management) (NN strategy)) (VP (VBG fitting) (NP (DT all) (NNS patients))))))) (, ,) (NP (NP (JJ cytotoxic) (NN chemotherapy)) (PP (IN with) (NP (NN docetaxel)))) (VP (VBZ is) (ADVP (RB currently)) (VP (VBN regarded) (PP (IN as) (NP (DT the) (JJ gold) (NN standard))))) (. .))
(S (ADVP (RB However)) (, ,) (NP (NNS tumors)) (VP (MD may) (VP (VP (VB regain) (NP (NN activity)) (PP (IN after) (NP (NN treatment) (NN conclusion)))) (CC and) (VP (VB become) (ADJP (JJ resistant) (PP (TO to) (NP (VB docetaxel))))))) (. .))
(S (NP (DT This) (NN situation)) (VP (VBZ calls) (PP (IN for) (NP (NP (JJ new) (NX (NX (NN delivery) (NNS strategies)) (CC and) (NX (NN drug) (NNS compounds)))) (VP (VBG enabling) (NP (DT an) (JJ improved) (JJ therapeutic) (NN outcome)))))) (. .))
(S (NP (NP (NN Combination)) (PP (IN of) (NP (NN docetaxel))) (PP (IN with) (NP (JJ antiangiogenic) (NN therapy)))) (VP (VBZ has) (VP (VBN been) (VP (VBN considered) (S (NP (DT a) (JJ promising) (NN strategy)))))) (. .))
(S (S (NP (NNP Bevacizumab)) (VP (VBZ is) (NP (DT the) (ADJP (RBS most) (JJ common)) (JJ antiangiogenic) (NN drug)))) (, ,) (CC but) (S (NP (JJ clinical) (NNS studies)) (VP (VBP have) (RB not) (VP (VBN revealed) (NP (NP (DT a) (JJ clear) (NN benefit)) (PP (IN from) (NP (NP (PRP$ its) (NN combination)) (PP (IN with) (NP (NN docetaxel))))))))) (. .))
(S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VP (VBP capitalize) (PP (IN on) (NP (NP (PRP$ our) (JJ prior) (NN work)) (PP (IN on) (NP (NP (JJ mathematical) (NN modeling)) (PP (IN of) (NP (NP (NN prostate) (NN cancer) (NN growth)) (VP (VBD subjected) (PP (TO to) (NP (VBN combined) (UCP (NN cytotoxic) (CC and) (JJ antiangiogenic)) (NNS therapies))))))))))) (, ,) (CC and) (VP (VB propose) (NP (NP (DT an) (JJ optimal) (NN control) (NN framework)) (SBAR (S (VP (TO to) (VP (ADVP (RB robustly)) (VB compute) (NP (NP (DT the) (JJ drug-independent) (UCP (NN cytotoxic) (CC and) (JJ antiangiogenic)) (NNS effects)) (VP (VBG enabling) (NP (NP (DT an) (JJ optimal) (JJ therapeutic) (NN control)) (PP (IN of) (NP (NN tumor) (NNS dynamics))))))))))))) (. .))
(S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT the) (NN formulation)) (PP (IN of) (NP (NP (DT the) (JJ optimal) (NN control) (NN problem)) (, ,) (SBAR (WHPP (IN for) (WHNP (WDT which))) (S (NP (PRP we)) (VP (VP (VBP prove) (NP (NP (DT the) (NN existence)) (PP (IN of) (NP (ADVP (IN at) (JJS least)) (DT a) (NN solution))))) (CC and) (VP (VB determine) (NP (DT the) (JJ necessary) (JJ first) (NN order) (NN optimality) (NNS conditions)))))))))) (. .))
(S (NP (PRP We)) (ADVP (RB then)) (VP (VBD present) (NP (NP (NP (JJ numerical) (NN algorithms)) (VP (VBN based) (PP (IN on) (NP (JJ isogeometric) (NN analysis))))) (SBAR (S (VP (TO to) (VP (VB run) (NP (DT a) (JJ preliminary) (NN simulation) (NN study)) (PP (IN over) (NP (NP (DT a) (JJ single) (NN cycle)) (PP (IN of) (NP (JJ combined) (NN therapy))))))))))) (. .))
(S (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (RB only) (JJ cytotoxic) (NN chemotherapy)) (VP (VBZ is) (VP (VBN required) (S (VP (TO to) (VP (VB optimize) (NP (JJ therapeutic) (NN performance))))))))))) (CC and) (S (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (PRP$ our) (NN framework)) (VP (MD can) (VP (VB produce) (NP (NP (JJ superior) (NNS solutions)) (PP (TO to) (NP (NP (VBN combined) (NN therapy)) (PP (IN with) (NP (NN docetaxel) (CC and) (NN bevacizumab)))))))))))) (. .))
